arrow
B

Brian D. Gonzalez

Moffitt Cancer Center
H指数:33
被引数:3,816

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perceived Facilitators and Barriers Inform Young Adult Cancer Survivors’ Preferences for Physical Activity and Diet Interventions: A Qualitative Study

感知到的促进因素和障碍因素影响年轻成年癌症幸存者对体力活动和饮食干预的偏好:一项定性研究

2026-09-040
OA
Comparing chemotherapy-induced nausea and vomiting between young adult vs non-young adult cancer patients

比较化疗诱导的恶心和呕吐在年轻成年癌症患者与非年轻成年癌症患者之间的差异

2026-08-180
OA
Lifestyle patterns and sleep disturbance among Black breast cancer survivors: results from the Women’s Circle of Health Follow-Up Study

生活方式模式与睡眠紊乱在黑人乳腺癌幸存者中的关系:来自女性健康随访研究的成果

2026-08-110
OAAI
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

idecabtagene vicleucel与ciltacabtagene autoleucel CAR-T治疗多发性骨髓瘤后的患者报告结局

2026-05-110
OAAI
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

将基线PSMA PET衍生参数与接受[177Lu]Lu-PSMA-617治疗患者的毒副作用、不良事件、疼痛及生活质量相关联:一项单中心回顾性研究

2026-02-010
PRE
Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity

Car-t治疗多发性骨髓瘤后患者报告结局的有意义变化: 种族和民族的差异

2026-01-230
OAAI
Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical care

功能性癌症治疗评估-免疫检查点调节剂17项症状指数(FACT-ICM-17)的验证,以促进其在研究和临床护理中的应用

CANCER
IF5.1
2025-10-150
OA
Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer

结直肠癌诊断后持续疲劳的遗传易感性

2025-09-010
OAAI
Hidden Costs of Endocrine Therapy for Black Breast Cancer Survivors: A Qualitative Examination of Patient and Provider Experiences

黑人乳腺癌幸存者内分泌治疗的隐性成本:对医患经验的一项定性考察

2025-07-050
OAAI
Associations Between Dietary Patterns and Quality of Life in a Longitudinal Cohort of Colorectal Cancer Survivors
2024-11-120
OAAI
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment
2024-09-090
OAAI
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T 161 Tb]Tb-PSMA-I&T

VIOLET的临床试验方案: [161 Tb] tb-psma-i & T转移性去势抵抗性前列腺癌患者放射配体治疗的单中心I/II期试验评估

2024-07-111
PRE